Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (361-370 of 643) with videos related to

Pageof 65
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumorsCinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.
Journal of Gynecologic Oncology|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analysesJung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Cancer Research Communications|February 9, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast CancerJonathan Goldberg, Na Qiao, Jennifer L Guerriero, et al.
JCI Insight|December 27, 2016
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyJiha Kim, Pedro Correa de Sampaio, Donna Marie Lundy, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Pageof 65

Showing results (361-370 of 643) with videos related to

Sort By:
Pageof 65
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumorsCinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.
Journal of Gynecologic Oncology|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analysesJung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Cancer Research Communications|February 9, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast CancerJonathan Goldberg, Na Qiao, Jennifer L Guerriero, et al.
JCI Insight|December 27, 2016
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyJiha Kim, Pedro Correa de Sampaio, Donna Marie Lundy, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Pageof 65